Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Mendelian randomization analyses for the relevance of anti-H. pylori IgG seropositivity with risk of CHD. by Jing Wang (6206297)

Subjects:

Three essential assumptions of the Mendelian randomization study. by Jing Wang (6206297)

Subjects:

Mendelian randomization analysis of the effect of anti-H. pylori IgG seropositivity on coronary heart disease (CHD). by Jing Wang (6206297)

Subjects:

Results data from this Mendelian randomization study. by Jing Wang (6206297)

Subjects:

Associations of anti-H. pylori IgG seropositivity with mediators. by Jing Wang (6206297)

Subjects:

Details of the GWAS data in this study. by Jing Wang (6206297)

Subjects:

Demographic and clinical data at baseline. by Karel Joineau (21799908)

Subjects:

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the neck-specific exercise with internet support (NSEIT) group and t... by Anneli Peolsson (7867601)

Sociodemographic, occupational, and clinical risk factors associated with low workability and results of Logistic regression analysis among diabetic workers. by Sarah A. Bolbol (21702891)

Subjects:

S1 File - by Changxu Wang (17826805)

“…Compared with the GA group, the VAS scores at 6 hours, 12 hours, and 24 hours after surgery in the TAP+GA group were significantly decreased, and the intraoperative consumption of remifentanil and the numbers of postoperative analgesic pump presses were significantly reduced (<i>P</i><0.05). …”

The flow chart of the study. by Changxu Wang (17826805)

“…Compared with the GA group, the VAS scores at 6 hours, 12 hours, and 24 hours after surgery in the TAP+GA group were significantly decreased, and the intraoperative consumption of remifentanil and the numbers of postoperative analgesic pump presses were significantly reduced (<i>P</i><0.05). …”

Summary of clinical outcomes after 9 months. by Jie Liu (15128)

Subjects: